To date, clinical studies of compounds based on such proteins as affibodies,ADAPTs, and DARPins for SPECT and PET have shown good tolerance, rapidelimination from the body, and the possibility to differentiate tumor lesionsdepending on the status of human epidermal growth factor receptor 2 HER2/ neu.An indisputable advantage of these methods over standard diagnostic approaches(FISH and IHC) is the possibility to perform simultaneous detection ofadditional tumor nodes and determine their molecular phenotype. The gene discussed is ERBB2; the disease is neoplasm.